Utilization patterns of second-line antibiotics in a health plan setting

Managed Care Interface

Volumn 16, Issue 9, 2003, Pages 29-33

  Jan, Saira A ^a,b   McDonald, Jennifer L ^c   Andros, Vickie ^d   Quilliam, Brian ^e  

^a Horizon Blue Cross Blue Shield N J ^*  (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Horizon BCBSNJ of New Jersey   (United States)

^d Project Management   (United States)

^e TOTAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFRADINE; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DIRITHROMYCIN; ENOXACIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; LORACARBEF; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TROLEANDOMYCIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; DATA BASE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG UTILIZATION; GRAM STAINING; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; PRESCRIPTION; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT FAILURE; URINARY TRACT INFECTION; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG UTILIZATION REVIEW; HEALTH SERVICES RESEARCH; HUMANS; MANAGED CARE PROGRAMS; UNITED STATES;

EID: 0141786895     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva, Switzerland, World Health Organization, 2001 (www.who.int/emc-documents/antimicrobial_resistance/whocdscsrdrs20012c.html).
2. Bishai W: Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. Clin Ther 2002;24:838-850.
3. Resistance of Streptococcus pneumoniae to fluoroquinolones -United States, 1995-1999. MMWR 2001;50:800-804.
4. Hillier SL, Magee JT, Howard AJ, et al: How strong is the evidence that antibiotic use is a risk factor for antibiotic-resistant, community-acquired urinary tract infection? J Antimicrob Chemother 2002;50:241-247.
5. Preventing drug resistance. Washington, DC, Centers for Disease Control and Prevention, April 2003 (www.cdc.gov/washington/overview/drugres.htm).
6. Cooper RJ, Hoffman JR, Bartlett JG, et al: Principles of appropriate antibiotic use for acute pharyngitis in adults: Background. Ann Intern Med 2001;134:509-517.
7. Snow V, Multur-Pilson C, Cooper RJ, et al: Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001;134:506-508.
8. Gonzales R, Bartlett JG, Besser RE, et al: Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: Background, specific aims, and methods. Ann Intern Med 2001;134:479-486.
9. McCracken GH: Considerations in selecting an antibiotic for treatment of acute otitis media. Pediatr Infect Dis J 1994;13:1054-1057.
10. Gilbert DN, Moellering RC, Sande MA: The Sanford Guide to Antimicrobial Therapy, 2001. Ed. 3. Hyde Park, VT, Antimicrobial Therapy, Inc., 2001.
11. Gonzales R, Steiner JF, Lum A, et al: Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999;281:1512-1519.
12. Norman DC: Management of antibiotic-resistant bacteria. J Am Geriatr Soc 2002;50(suppl):242-246.
13. McCaig LF, Besser RE, Hughes JM: Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003;9:432-437.
14. Avorn J, Solomon DH: Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-135.
15. Snow V, Mottur-Pilson C, Gonzales R: Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults. Ann Intern Med 2001;134:487-489.